Cancer-related inflammation and treatment effectiveness
Abstract
Inflammation is a recognised hallmark of cancer that substantially contributes to the development and progression of malignancies. In established cancers, there is increasing evidence for the roles that local immune response and systemic inflammation have in progression of tumours and survival of patients with cancer. This knowledge provides an opportunity to target these inflammatory responses to improve patient outcomes. In this Review, we examine the complex interplay between local immune responses and systemic inflammation, and their influence on clinical outcomes, and propose potential anti-inflammatory interventions for patients with cancer.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The systemic inflammatory response reflects tumor immune cytokine activity and decreased nutritional status, such as appetite loss or fatigue.
“Furthermore, the systemic inflammatory response reflects tumor immune cytokine activity and decreased nutritional status, such as appetite loss or fatigue(28,29).”
From Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy. (2024) · cites this paper as [28]
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 98 · Cited by 2,193
- Authors
- Diakos, C. I., Charles, K. A., McMillan, D. C., & Clarke, S. J.
- Affiliations
- The University of Sydney (AU)
- Glasgow Royal Infirmary (GB)
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 15
- Issue
- 11
- Pages
- e493-e503
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2014229457
- Cited by
- 2,193
- References
- 98
- Citations by year
- 2026: 162 · 2025: 237 · 2024: 275 · 2023: 301 · 2022: 293 · 2021: 268 · 2020: 206 · 2019: 175 · 2018: 96 · 2017: 74 · 2016: 62 · 2015: 42 · 2014: 1
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Health Sciences › Medicine › Psychiatry and Mental health › Cancer, Stress, Anesthesia, and Immune Response
- Keywords
- tumor inflammation, systemic inflammation, local immune response, tumor progression, cancer survival, anti-inflammatory therapy, cancer immunotherapy, treatment effectiveness
- MeSH terms
- Female, Humans, Immunity, Innate, Inflammation, Male, Neoplasm Invasiveness, Neoplasm Staging, Neoplasms, Prostatectomy, Survival Analysis, Treatment Outcome, Disease Progression, Risk Assessment, Antineoplastic Agents, Hormonal, Radiotherapy, Conformal, Watchful Waiting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
